Millennium Management
ACRS icon

Millennium Management’s Aclaris Therapeutics ACRS Stock Holding History

Millennium Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.84M Sell
756,127
-297,119
-28% -$1M ﹤0.01% 3522
2025
Q4 		$3.17M Sell
1,053,246
-501,212
-32% -$1.27M ﹤0.01% 3494
2025
Q3 		$2.95M Sell
1,554,458
-2,282,922
-59% -$3.98M ﹤0.01% 3679
2025
Q2 		$5.45M Sell
3,837,380
-296,768
-7% -$402K ﹤0.01% 2892
2025
Q1 		$6.33M Buy
4,134,148
+2,175,101
+111% +$4.64M ﹤0.01% 2637
2024
Q4 		$4.86M Sell
1,959,047
-1,046,551
-35% -$2.6M ﹤0.01% 2844
2024
Q3 		$3.46M Sell
3,005,598
-331,252
-10% -$406K ﹤0.01% 3178
2024
Q2 		$3.67M Buy
3,336,850
+63,358
+2% +$74.5K ﹤0.01% 3011
2024
Q1 		$4.06M Sell
3,273,492
-205,869
-6% -$245K ﹤0.01% 3087
2023
Q4 		$3.65M Buy
3,479,361
+1,511,381
+77% +$4.61M ﹤0.01% 3066
2023
Q3 		$13.5M Buy
1,967,980
+1,140,896
+138% +$9.75M 0.01% 1759
2023
Q2 		$8.58M Buy
827,084
+766,221
+1,259% +$6.93M ﹤0.01% 2168
2023
Q1 		$492K Sell
60,863
-147,035
-71% -$1.87M ﹤0.01% 4611
2022
Q4 		$3.27M Buy
207,898
+3,993
+2% +$64.2K ﹤0.01% 3144
2022
Q3 		$3.21M Buy
203,905
+5,111
+3% +$80.5K ﹤0.01% 3322
2022
Q2 		$2.77M Buy
198,794
+142,581
+254% +$2M ﹤0.01% 3375
2022
Q1 		$969K Sell
56,213
-296,294
-84% -$4.04M ﹤0.01% 4556
2021
Q4 		$5.13M Buy
352,507
+31,316
+10% +$474K ﹤0.01% 2883
2021
Q3 		$5.78M Buy
321,191
+120,827
+60% +$1.94M ﹤0.01% 2702
2021
Q2 		$3.52M Sell
200,364
-142,883
-42% -$3.25M ﹤0.01% 3232
2021
Q1 		$8.65M Buy
343,247
+134,321
+64% +$2.63M 0.01% 1946
2020
Q4 		$1.35M Sell
208,926
-72,872
-26% -$307K ﹤0.01% 3523
2020
Q3 		$724 Sell
281,798
-103,137
-27% -$231K ﹤0.01% 3355
2020
Q2 		$624K Buy
+384,935
New +$516K ﹤0.01% 3268
2020
Q1 		– Sell
-281,848
Closed -$533K – 3778
2019
Q4 		$533K Buy
281,848
+21,397
+8% +$35.5K ﹤0.01% 3342
2019
Q3 		$281K Buy
260,451
+225,065
+636% +$319K ﹤0.01% 3598
2019
Q2 		$77K Buy
35,386
+14,484
+69% +$78.9K ﹤0.01% 3924
2019
Q1 		$125K Buy
+20,902
New +$139K ﹤0.01% 3818
2018
Q2 		– Sell
-110,827
Closed -$1.94M – 3749
2018
Q1 		$1.94M Buy
110,827
+99,029
+839% +$2.1M ﹤0.01% 2340
2017
Q4 		$291K Buy
+11,798
New +$287K ﹤0.01% 3364
2017
Q3 		– Sell
-15,092
Closed -$409K – 3461
2017
Q2 		$409K Buy
15,092
+5,273
+54% +$143K ﹤0.01% 2903
2017
Q1 		$293K Buy
+9,819
New +$283K ﹤0.01% 3054

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management's ACRS Position: Q1 2026 in Review

Millennium Management reduced its Aclaris Therapeutics (ACRS) stake by 28% in Q1 2026, selling an estimated $1M and leaving 756,127 shares worth $2.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3522.

Millennium Management first reported a position in ACRS in Q1 2017 and has held it in 32 quarters since. The position peaked at $13.5M in Q3 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Millennium Management held 756,127 shares of Aclaris Therapeutics worth $2.84M as of Q1 2026.
  • Millennium Management sold 297,119 Aclaris Therapeutics shares in Q1 2026, an estimated $1M.
  • Aclaris Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3522 holding.
  • Millennium Management first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 32 quarters since.
  • Millennium Management's Aclaris Therapeutics position peaked at $13.5M in Q3 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.